

CELGENE CORP /DE/  
Form 8-K  
October 17, 2016

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The  
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): October 17, 2016

**CELGENE CORPORATION**

(Exact name of registrant as specified in its charter)

Delaware

001-34912

22-2711928

(Commission File Number) (IRS Employer Identification No.)

Edgar Filing: CELGENE CORP /DE/ - Form 8-K

(State or other jurisdiction of  
incorporation)

86 Morris Avenue, Summit, New Jersey 07901  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (908) 673-9000

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 OTHER EVENTS**

On October 17, 2016, Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, issued a press release providing additional data on the ongoing phase 1b CD-001 study exploring the effects of oral GED-0301 (mongersen) on both endoscopic and clinical outcomes in patients with active Crohn's disease. Attached hereto and incorporated herein by reference as Exhibit 99.1 is the press release announcement.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.**

Exhibit 99.1 – Press Release dated October 17, 2016

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**CELGENE  
CORPORATION**

Date: October 17, 2016 By: /s/ Peter N. Kellogg  
Peter N. Kellogg  
Executive Vice  
President and  
Chief Financial  
Officer  
(principal financial  
and accounting  
officer)

EXHIBIT INDEX

**Exhibit No. Description**

99.1 Press Release dated October 17, 2016